Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)
Shah, Payal Deepak, Chandarlapaty, Sarat, Dickler, Maura N., Ulaner, Gary, Zamora, Stephen James, Sterlin, Valentina, Iasonos, Alexia, Coughlin, Christina Marie, Morozov, Alex, Ero, Joy, Rosen, Neal, Gilewski, Teresa, Fornier, Monica Nancy, Sklarin, Nancy T., Berger, Michael F., Moynahan, Mary Ellen, Hudis, Clifford A., Baselga, Jose, Modi, Shanu
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
Successful implementation of a novel trial model: The Signature program
Peguero, Julio Antonio, Knost, James A., Bauer, Todd Michael, Taylor, Matthew Hiram, Braiteh, Fadi S., Eder, Joseph Paul, Safran, Howard, O'Neil, Bert H., Alva, Ajjai Shivaram, Nadauld, Lincoln, Joshi, Prashant, Miranda, Flora, Sidhu, Rajinder, Ero, Joy, Slosberg, Eric Daniel, Lebedinsky, Claudia, Kang, Barinder, Parasuraman, Sudha, Piha-Paul, Sarina Anne
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article